Secukinumab provides greater 52-week sustained relief in dermatology-specific quality-of-life impact than ustekinumab Meeting Abstract

publication date

  • June 1, 2017

webpage

published in

start page

  • AB230

end page

  • AB230

volume

  • 76

issue

  • 6